{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-044883","form_type":"8-K","ticker":null,"cik":"0001404123","company_name":"1Life Healthcare Inc","filed_at":"2023-02-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.779790+00:00","generated_at":"2026-06-19T04:31:50.339511+00:00","sec_items":["1.01","1.02","2.01","2.04","3.01","3.03","5.01","5.02","5.03","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"One Medical completes acquisition by Amazon; shareholders receive $18.00 per share in cash","bullets":["Merger effective Feb 22, 2023; each share of ONEM converted to $18.00 cash, no interest.","All directors resigned effective at closing; company becomes indirect wholly owned subsidiary of Amazon.","Convertible notes (3.00% due 2025) conversion changed to $405.0936 cash per $1,000 principal; holders have repurchase right until March 22, 2023.","Shares to be delisted from Nasdaq; company will file Form 15 to suspend SEC reporting obligations.","Interim loan agreement with Amazon Services LLC terminated upon closing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-044883","json":"https://secwatch.observer/filing/0001193125-23-044883.json","markdown":"https://secwatch.observer/filing/0001193125-23-044883.md","text":"https://secwatch.observer/filing/0001193125-23-044883.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1404123/000119312523044883/0001193125-23-044883-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1404123/000119312523044883/d468299d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T04:31:50.339511+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3e9ea5d71911c4a95039ececfc91923f66931a3c","claim":"1Life Healthcare Inc faced acceleration on convertible notes of approximately $316.3 million aggregate principal amount.","evidence_excerpt":"by and between the Company and the Convertible Notes Trustee, governing the Company’s 3.00% Senior Convertible Notes due 2025 (the “Convertible Notes”), of which approximately $316.3 million aggregate principal amount was outstanding on February 21, 2023. The Supplemental Indenture provides that, from and after the Effective Time, the right to convert each $1,000","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1404123/000119312523044883/0001193125-23-044883-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"approximately $316.3 million aggregate principal amount"},{"label":"Event","value":"acceleration"}],"fact_type":"debt_financing"},{"claim_id":"05b7014e8b","claim":"Robert R. Schmidt departed as Director at 1Life Healthcare Inc.","evidence_excerpt":"each of Paul R. Auvil, Mark S. Blumenkranz, Bruce W. Dunlevie, Kalen F. Holmes, David P. Kennedy, Freda C. Lewis-Hall, Robert R. Schmidt, Scott C. Taylor and Mary Ann Tocio ceased serving as a member of the board of directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1404123/000119312523044883/0001193125-23-044883-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"36ef3d91cd","claim":"David P. Kennedy departed as Director at 1Life Healthcare Inc.","evidence_excerpt":"each of Paul R. Auvil, Mark S. Blumenkranz, Bruce W. Dunlevie, Kalen F. Holmes, David P. Kennedy, Freda C. Lewis-Hall, Robert R. Schmidt, Scott C. Taylor and Mary Ann Tocio ceased serving as a member of the board of directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1404123/000119312523044883/0001193125-23-044883-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"618fa7c10f","claim":"Freda C. Lewis-Hall departed as Director at 1Life Healthcare Inc.","evidence_excerpt":"each of Paul R. Auvil, Mark S. Blumenkranz, Bruce W. Dunlevie, Kalen F. Holmes, David P. Kennedy, Freda C. Lewis-Hall, Robert R. Schmidt, Scott C. Taylor and Mary Ann Tocio ceased serving as a member of the board of directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1404123/000119312523044883/0001193125-23-044883-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"882f454d62","claim":"Scott C. Taylor departed as Director at 1Life Healthcare Inc.","evidence_excerpt":"each of Paul R. Auvil, Mark S. Blumenkranz, Bruce W. Dunlevie, Kalen F. Holmes, David P. Kennedy, Freda C. Lewis-Hall, Robert R. Schmidt, Scott C. Taylor and Mary Ann Tocio ceased serving as a member of the board of directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1404123/000119312523044883/0001193125-23-044883-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"af9caf0e8c","claim":"Paul R. Auvil departed as Director at 1Life Healthcare Inc.","evidence_excerpt":"each of Paul R. Auvil, Mark S. Blumenkranz, Bruce W. Dunlevie, Kalen F. Holmes, David P. Kennedy, Freda C. Lewis-Hall, Robert R. Schmidt, Scott C. Taylor and Mary Ann Tocio ceased serving as a member of the board of directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1404123/000119312523044883/0001193125-23-044883-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"b7598463d4","claim":"Kalen F. Holmes departed as Director at 1Life Healthcare Inc.","evidence_excerpt":"each of Paul R. Auvil, Mark S. Blumenkranz, Bruce W. Dunlevie, Kalen F. Holmes, David P. Kennedy, Freda C. Lewis-Hall, Robert R. Schmidt, Scott C. Taylor and Mary Ann Tocio ceased serving as a member of the board of directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1404123/000119312523044883/0001193125-23-044883-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"d6313dd8e5","claim":"Bruce W. Dunlevie departed as Director at 1Life Healthcare Inc.","evidence_excerpt":"each of Paul R. Auvil, Mark S. Blumenkranz, Bruce W. Dunlevie, Kalen F. Holmes, David P. Kennedy, Freda C. Lewis-Hall, Robert R. Schmidt, Scott C. Taylor and Mary Ann Tocio ceased serving as a member of the board of directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1404123/000119312523044883/0001193125-23-044883-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"f5956af795","claim":"Mary Ann Tocio departed as Director at 1Life Healthcare Inc.","evidence_excerpt":"each of Paul R. Auvil, Mark S. Blumenkranz, Bruce W. Dunlevie, Kalen F. Holmes, David P. Kennedy, Freda C. Lewis-Hall, Robert R. Schmidt, Scott C. Taylor and Mary Ann Tocio ceased serving as a member of the board of directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1404123/000119312523044883/0001193125-23-044883-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"f73270d7d9","claim":"Mark S. Blumenkranz departed as Director at 1Life Healthcare Inc.","evidence_excerpt":"each of Paul R. Auvil, Mark S. Blumenkranz, Bruce W. Dunlevie, Kalen F. Holmes, David P. Kennedy, Freda C. Lewis-Hall, Robert R. Schmidt, Scott C. Taylor and Mary Ann Tocio ceased serving as a member of the board of directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1404123/000119312523044883/0001193125-23-044883-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"38fb7416b85c9c76f4be4037a2a6ca7935b787c4","claim":"1Life Healthcare Inc underwent a change of control involving Amazon.com, Inc. for $18.00 in cash, without interest (closed 2023-02-22).","evidence_excerpt":"in the treasury of the Company or owned by Parent or Merger Sub and any dissenting Shares, ceased to be outstanding and was converted automatically into the right to receive $18.00 in cash, without interest (the “Merger Consideration”). At the Effective Time, all Shares underlying vested Company stock options with an exercise price per Share that was less","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1404123/000119312523044883/0001193125-23-044883-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Counterparty","value":"Amazon.com, Inc."},{"label":"Consideration","value":"$18.00 in cash, without interest"},{"label":"Closing","value":"2023-02-22"}],"fact_type":"ma_transaction"},{"claim_id":"35f1f68cab0317976a95e099b562546ceab775c1","claim":"1Life Healthcare Inc terminated Interim Loan and Guaranty Agreement with Amazon.com Services LLC (effective 2023-02-22).","evidence_excerpt":"On February 22, 2023, the Company terminated the Interim Loan and Guaranty Agreement, dated as of November 14, 2022 (the “Interim Loan and Guaranty Agreement”), by and between Amazon.com Services LLC and the Company.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1404123/000119312523044883/0001193125-23-044883-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Amazon.com Services LLC"},{"label":"Effective","value":"2023-02-22"}],"fact_type":"material_agreement"},{"claim_id":"37bddf5eb968dff4669d6534b493087457346e6e","claim":"1Life Healthcare Inc amended First Supplemental Indenture with U.S. Bank Trust Company, National Association (as successor to U.S. Bank National Association) valued at approximately $316.3 million aggregate principal amount (effective 2023-02-22).","evidence_excerpt":"On February 22, 2023, the Company and U.S. Bank Trust Company, National Association (as successor to U.S. Bank National Association) (the “Convertible Notes Trustee”), entered into a First Supplemental Indenture (the “Supplemental Indenture”), dated as of February 22, 2023, which supplements the Indenture, dated as of May 29, 2020 (as supplemented by the Supplemental Indenture, the “Indenture”), by and between the Company and the Convertible Notes Trustee, governing the Company’s 3.00% Senior Convertible Notes due 2025 (the “Convertible Notes”), of which approximately $316.3 million aggregate principal amount was outstanding on February 21, 2023.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1404123/000119312523044883/0001193125-23-044883-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"notes offering"},{"label":"Counterparty","value":"U.S. Bank Trust Company, National Association (as successor to U.S. Bank National Association)"},{"label":"Value","value":"approximately $316.3 million aggregate principal amount"},{"label":"Effective","value":"2023-02-22"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}